UBS AG has reiterated its "Buy" rating for Novartis AG, with a target price of 111 Swiss francs.
Analyst Matthew Weston observed that Novartis exceeded consensus estimates with a slight sales surprise, reporting core earnings per share (EPS) that were 6 percent higher.
Novartis shares are currently trading at 102.40 EUR, representing a decline of 4.12 EUR or 3.87%. In Swiss francs, the shares are priced at 95.74 CHF, down 4.07 CHF or 4.08%.
The analysis, published on October 29, 2024, highlights Novartis' strong performance in line with market expectations.